Triple negative breast cancers are found to have poor prognosis. It has been postulated that pathological complete response (pCR) to neoadjuvant chemotherapy can be a surrogate for survival in TNBC. Various combinations of chemotherapeutic agents have been tried to improve the pCR rates including addition of platinum compounds. Although western data is available no studies till date have reported this from a developing world. This study intends to find out the pCR rates and the disease free survival and the overall survival for patients treated with neoadjuvant chemotherapy (NACT) with paclitaxel and carboplatin in locally advanced TNBC. The study was conducted at a rural tertiary cancer centre in South India. This was a retrospective analysis of medical records of patients who underwent NACT with paclitaxel and carboplatin from 1^st January 2014 to 31^st December 2018 at. Malabar Cancer Centre. A total of 33 patients underwent chemotherapy with paclitaxel and carboplatin during the study period. The median age was 51 years. 59% of patients had stage IIIA disease.96% of patients took all 12 cycles of NACT. 43% of patients had complete response to neo adjuvant chemotherapy whereas 57% of patients had partial response to chemotherapy. This was comparable to the available literature. The four year disease free survival was 81% and the four year overall survival was 86% in this study. No statistically significant difference in survival could be found in those patients who achieved pCR when compared to those who did not. Studies with a larger number of patients are needed to throw light in this aspect.

References

1.       Trivers KF, Lund MJ, Porter PL, Liff JM, Flagg EW, Coates RJ, Eley JW. The epidemiology of triple-negative breast cancer, including race. Cancer Causes Control. 2009 Sep;20(7):1071-82. doi: 10.1007/s10552-009-9331-1, PMID 19343511.

2.       Foulkes WD, Smith IE, Reis-Filho JS. Triple-negative breast cancer. N Engl J Med. 2010 Nov 11;363(20):1938-48. doi: 10.1056/NEJMra1001389, PMID 21067385.

3.       Kennedy RD, Quinn JE, Johnston PG, Harkin DP. BRCA1: mechanisms of inactivation and implications for management of patients [internet]. Lancet. 2002;360(9338):1007-14. doi: 10.1016/S0140-6736(02)11087-7, PMID 12383682.

4.       Ademuyiwa FO, Groman A, Hong CC, Miller A, Kumar S, Levine E, Erwin D, Ambrosone C. Time-trends in survival in young women with breast cancer in a SEER population-based study. Breast Cancer Res Treat. 2013;138(1):241-8. doi: 10.1007/s10549-013-2425-1, PMID 23371505.

5.       Senkus E, Kyriakides S, Ohno S, Penault-Llorca F, Poortmans P, Rutgers E, Zackrisson S, Cardoso F, ESMO Guidelines Committee. Primary breast cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol. 2015 Sep 1;26;Suppl 5:v8-30. doi: 10.1093/annonc/mdv298, PMID 26314782.

6.       Huober J, Von Minckwitz G, Denkert C, Tesch H, Weiss E, Zahm DM, Belau A, Khandan F, Hauschild M, Thomssen C, Högel B, Darb-Esfahani S, Mehta K, Loibl S. Effect of neoadjuvant anthracycline-taxane-based chemotherapy in different biological breast cancer phenotypes: overall results from the GeparTrio study. Breast Cancer Res Treat. 2010 Nov;124(1):133-40. doi: 10.1007/s10549-010-1103-9, PMID 20697801.

7.       Liedtke C, Mazouni C, Hess KR, André F, Tordai A, Mejia JA, Symmans WF, Gonzalez-Angulo AM, Hennessy B, Green M, Cristofanilli M, Hortobagyi GN, Pusztai L. Response to neoadjuvant therapy and long-term survival in patients with triple-negative breast cancer. J Clin Oncol. 2008 Mar 10;26(8):1275-81. doi: 10.1200/JCO.2007.14.4147, PMID 18250347.

8.       Sikov WM, Dizon DS, Strenger R, Legare RD, Theall KP, Graves TA, Gass JS, Kennedy TA, Fenton MA. Frequent pathologic complete responses in aggressive stages II to III breast cancers with every-4-week carboplatin and weekly paclitaxel with or without trastuzumab: A brown university oncology group study. J Clin Oncol. 2009 Oct 1;27(28):4693-700. doi: 10.1200/JCO.2008.21.4163, PMID 19720916.

9.       Chang HR, Glaspy J, Allison MA, Kass FC, Elashoff R, Chung DU, Gornbein J. Differential response of triple-negative breast cancer to a docetaxel and carboplatin-based neoadjuvant treatment. Cancer. 2010 Sep 15;116(18):4227-37. doi: 10.1002/cncr.25309, PMID 20549829.

10.     Chen XS, Nie XQ, Chen CM, Wu JY, Wu J, Lu JS, Shao ZM, Shen ZZ, Shen KW. Weekly paclitaxel plus carboplatin is an effective nonanthracycline-containing regimen as neoadjuvant chemotherapy for breast cancer. Ann Oncol. 2010 Mar 8;21(5):961-7. doi: 10.1093/annonc/mdq041, PMID 20211870.

11.     Roy V, Pockaj BA, Allred JB, Apsey H, Northfelt DW, Nikcevich D, Mattar B, Perez EA. A phase II trial of docetaxel and carboplatin administered every 2 weeks as preoperative therapy for stage II or III breast cancer: NCCTG study N0338. Am J Clin Oncol. 2013 Dec;36(6):540-4. doi: 10.1097/COC.0b013e318256f619, PMID 22868240.

12.     Herbst RS. Review of epidermal growth factor receptor biology. Int J Radiat Oncol Biol Phys. 2004;59(2);Suppl:21-6. doi: 10.1016/j.ijrobp.2003.11.041, PMID 15142631.

13.     Zhang H, Berezov A, Wang Q, Zhang G, Drebin J, Murali R, Greene MI. ErbB receptors: from oncogenes to targeted cancer therapies [internet]. J Clin Invest. 2007;117(8):2051-8. doi: 10.1172/JCI32278, PMID 17671639.

14.     Sikov WM, Berry DA, Perou CM, Singh B, Cirrincione CT, Tolaney SM, Kuzma CS, Pluard TJ, Somlo G, Port ER, Golshan M, Bellon JR, Collyar D, Hahn OM, Carey LA, Hudis CA, Winer EP. Impact of the addition of carboplatin and/or bevacizumab to neoadjuvant once-per-week paclitaxel followed by dose-dense doxorubicin and cyclophosphamide on pathologic complete response rates in stage II to III triple-negative breast cancer: CALGB 40603 (Alliance). J Clin Oncol. 2015 Jan 1;33(1):13-21. doi: 10.1200/JCO.2014.57.0572, PMID 25092775.

15.     Sikov WM, Polley M-Y, Twohy E, Perou CM, Singh B, Berry DA, Tolaney SM, Somlo G, Port ER, Ma CX, Kuzma CS, Mamounas EP, Golshan M, Bellon JR, Collyar DE, Hahn OM, Hudis CA, Winer EP, Partridge AH, Carey LA, CALGB. (Alliance) 40603: long-term outcomes (LTOs) after neoadjuvant chemotherapy (NACT) +/− carboplatin (Cb) and bevacizumab (Bev) in triple-negative breast cancer (TNBC). J Clin Oncol. 2019 May 20;37(15):591. doi: 10.1200/JCO.2019.37.15_suppl.591.

16.     Von Minckwitz G, Schneeweiss A, Loibl S, Salat C, Denkert C, Rezai M, Blohmer JU, Jackisch C, Paepke S, Gerber B, Zahm DM, Kümmel S, Eidtmann H, Klare P, Huober J, Costa S, Tesch H, Hanusch C, Hilfrich J, Khandan F, Fasching PA, Sinn BV, Engels K, Mehta K, Nekljudova V, Untch M. Neoadjuvant carboplatin in patients with triple-negative and HER2-positive early breast cancer (GeparSixto; GBG 66): A randomised phase 2 trial. Lancet Oncol. 2014;15(7):747-56. doi: 10.1016/S1470-2045(14)70160-3, PMID 24794243.

17.     Edge SB, Compton CC. The American Joint Committee on Cancer: the 7th edition of the AJCC cancer staging manual and the future of TNM. Ann Surg Oncol. 7th ed. 2010;17(6):1471-4. doi: 10.1245/s10434-010-0985-4, PMID 20180029.

18.     Castrellon AB, Velez M, Nguyen SM, Blaya M, Barnick S, Dumais K, LeCroy N, Raez LE. Evaluation of weekly paclitaxel plus carboplatin followed by anthracycline chemotherapy on the neoadjuvant treatment of patients with triple-negative breast cancer. Hematol Oncol Stem Cell Ther. 2018 Mar 1;11(1):30-3. doi: 10.1016/j.hemonc.2017.07.006, PMID 29100977.

19.     Campos Gomez S, Campos Gomez KA, Garcia Garces M, Morelos G, Hernandez Alvarez J. Neoadjuvant carboplatin and docetaxel in locally advanced triple negative breast cancer: A Hispanic trial. J Clin Oncol. 2016 May 20;34(15_suppl):e12554-. doi: 10.1200/JCO.2016.34.15_suppl.e12554.

20.     Alba E, Chacon JI, Lluch A, Anton A, Estevez L, Cirauqui B, Carrasco E, Calvo L, Segui MA, Ribelles N, Alvarez R, Sanchez-Muñoz A, Sanchez R, Garcia-Asenjo JA, Rodriguez-Martin C, Escudero MJ, Albanell J. A randomized phase II trial of platinum salts in basal-like breast cancer patients in the neoadjuvant setting. Results from the GEICAM/2006-03, multicenter study. Breast Cancer Res Treat. 2012 Nov;136(2):487-93. doi: 10.1007/s10549-012-2100-y, PMID 23053638.

21.     Ando M, Yamauchi H, Aogi K, Shimizu S, Iwata H, Masuda N, Yamamoto N, Inoue K, Ohono S, Kuroi K, Hamano T, Sukigara T, Fujiwara Y. Randomized phase II study of weekly paclitaxel with and without carboplatin followed by cyclophosphamide/epirubicin/5-fluorouracil as neoadjuvant chemotherapy for stage II/IIIA breast cancer without HER2 overexpression. Breast Cancer Res Treat. 2014;145(2):401-9. doi: 10.1007/s10549-014-2947-1, PMID 24728578.

22.     Gluz O, Nitz U, Liedtke C, Christgen M, Grischke EM, Forstbauer H, Braun M, Warm M, Hackmann J, Uleer C, Aktas B, Schumacher C, Bangemann N, Lindner C, Kuemmel S, Clemens M, Potenberg J, Staib P, Kohls A, von Schumann R, Kates R, Kates R, Schumacher J, Wuerstlein R, Kreipe HH, Harbeck N. Comparison of neoadjuvant nab-paclitaxel+carboplatin vs nab-paclitaxel+gemcitabine in triple-negative breast cancer: randomized WSG-ADAPT-TN trial results. J Natl Cancer Inst. 2018;110(6):628-37. doi: 10.1093/jnci/djx258, PMID 29228315.

23.     Loibl S, O’Shaughnessy J, Untch M, Sikov WM, Rugo HS, McKee MD, Huober J, Golshan M, von Minckwitz G, Maag D, Sullivan D, Wolmark N, McIntyre K, Ponce Lorenzo JJ, Metzger Filho O, Rastogi P, Symmans WF, Liu X, Geyer CE. Addition of the PARP inhibitor veliparib plus carboplatin or carboplatin alone to standard neoadjuvant chemotherapy in triple-negative breast cancer (BrighTNess): a randomised, phase 3 trial. Lancet Oncol. 2018 Apr 1;19(4):497-509. doi: 10.1016/S1470-2045(18)30111-6, PMID 29501363.

24.     Sandhu GS, Erqou S, Patterson H, Mathew A. Prevalence of triple-negative breast cancer in India: systematic review and meta-analysis. J Glob Oncol. 2016 Dec;2(6):412-21. doi: 10.1200/JGO.2016.005397, PMID 28717728.

25.     Mary N, Nisha C, Jerome K, Vaz C, Nair V. Prevalence of triple negative breast cancers from a hospital-based cancer registry in a tertiary care hospital in Kerala, South India. World J Public Heal. 2019 Jul 16;4(2):43. doi: 10.11648/j.wjph.20190402.13.